The GLOBE Final Rule: A Narrow Model that May Be a Bellwether for Most Favored Nation Pricing
This update summarizes the Global Benchmark for Efficient Drug Pricing Model, addresses key considerations for industry, and assesses what may come next.
Editor
Karen A. Spindler
Partner
Webcast: Anticipating and Resolving Potential Licensing and Collaboration Disputes Before They Arise
Join Gibson Dunn lawyers for the first recorded session of a three-part series following a single life sciences collaboration and licensing dispute across its full lifecycle to explore how contract language, forum selection, and science shape leverage, timing, proof, and outcomes.
MFN Goes Mid-Market: Nine More Drugmakers Sign Medicaid Pricing Deals as the September 29 Tariff Deadline Approaches
On August 31, 2026, the White House announced most-favored-nation (“MFN”) pricing agreements with nine additional pharmaceutical manufacturers: Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB. The agreements bring the total number of manufacturers with MFN deals to 26, which the White House says covers 89 percent of the branded drug market.
How ‘Most Favored Nation’ Regime Affects Biopharma Deals
This article describes the current state-of-play with MFN and key deal drafting considerations. Life sciences dealmaking is running at a record pace — straight into a pricing regime that is still being written. According to Gibson Dunn’s July biopharma M&A survey, the first half of 2026 saw 13 announced acquisitions of public biopharma targets ranging…
Royalty Finance Has Found Its Footing. Here’s What Six Years of Data Tell Us.
We just published Gibson Dunn’s 2026 Royalty Finance Market Update — a comprehensive analysis of 133 life sciences royalty transactions from 2020 through 2025, totaling $32.7 billion in aggregate value. A few findings stood out to us as genuinely worth flagging for practitioners in the space.
One and Done: FDA’s New Single-Trial Default and What It Means for Drug Developers, Investors, and Counsel
On February 18, 2026, FDA Commissioner Martin Makary and Vinay Prasad, then-Chief Medical and Scientific Officer and Director of the Center for Biologics Evaluation and Research, published a landmark policy announcement in the New England Journal of Medicine that a single adequate and well-controlled pivotal trial — supplemented by confirmatory evidence — is now the…